X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2021-02-22 | SNSE | Sensei Biotherapeutics, Inc. | Cambrian Biopharma Inc | 10% | P - Purchase | $18.88 | +9,802 | 4,712,494 | 0% | +$185,062 | ||||||
2021-02-22 | SNSE | Sensei Biotherapeutics, Inc. | Peyer James | Dir, 10% | P - Purchase | $18.88 | +9,802 | 4,712,494 | 0% | +$185,062 | ||||||
| M | 2021-02-22 | SDGR | Schrodinger, Inc. | Shaw David E | 10% | S - Sale | $112.24 | -457,693 | 8,862,154 | -5% | -$51,373,433 | |||||
| DM | 2021-02-22 | SDGR | Schrodinger, Inc. | Daniel Jennifer | SVP, CHRO | S - Sale+OE | $108.96 | -6,688 | 6,688 | -50% | -$728,724 | |||||
2021-02-22 | ARWR | Arrowhead Pharmaceuticals, Inc. | Given Douglas B | Dir | S - Sale | $88.73 | -1,125 | 145,743 | -1% | -$99,821 | ||||||
| D | 2021-02-22 | ABBV | Abbvie Inc. | Sorg Elaine K. | SVP, US Commercial Operations | S - Sale+OE | $104.72 | -20,195 | 32,751 | -38% | -$2,114,732 | |||||
| M | 2021-02-22 | HGEN | Humanigen, Inc | Nomis Bay Ltd. | 10% | S - Sale | $22.29 | -103,220 | 5,662,542 | -2% | -$2,301,023 | |||||
| DM | 2021-02-22 | STOK | Stoke Therapeutics, Inc. | Tulipano Stephen J | CFO | S - Sale+OE | $58.86 | -30,000 | 602 | -98% | -$1,765,896 | |||||
2021-02-22 | FOLD | Amicus Therapeutics, Inc. | Crowley John F | COB, CEO | S - Sale | $11.98 | -7,682 | 909,101 | -1% | -$92,027 | ||||||
2021-02-22 | CARA | Cara Therapeutics, Inc. | Goncalves Joana | Chief Medical Officer | S - Sale | $19.73 | -2,000 | 26,075 | -7% | -$39,460 | ||||||
| D | 2021-02-22 | MRSN | Mersana Therapeutics, Inc. | Lowinger Timothy B | Chief Science, Tech. Officer | S - Sale+OE | $20.01 | -8,203 | 31,444 | -21% | -$164,142 | |||||
2021-02-22 | ARDX | Ardelyx, Inc. | Blanks Robert | See Remarks | S - Sale | $6.88 | -593 | 112,729 | -1% | -$4,081 | ||||||
2021-02-22 | ARDX | Ardelyx, Inc. | Jacobs Jeffrey W | Chief Scientific Officer | S - Sale | $6.88 | -702 | 124,772 | -1% | -$4,832 | ||||||
2021-02-22 | ARDX | Ardelyx, Inc. | Rodriguez Susan | Chief Commercial Officer | S - Sale | $6.88 | -611 | 45,914 | -1% | -$4,205 | ||||||
2021-02-22 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale | $6.88 | -2,534 | 242,652 | -1% | -$17,440 | ||||||
2021-02-22 | ARDX | Ardelyx, Inc. | Rosenbaum David P. | Chief Development Officer | S - Sale | $6.88 | -805 | 272,608 | 0% | -$5,540 | ||||||
2021-02-22 | ARDX | Ardelyx, Inc. | Renz Justin A | CFO | S - Sale | $6.88 | -608 | 41,290 | -1% | -$4,185 | ||||||
2021-02-22 | ARDX | Ardelyx, Inc. | Grammer Elizabeth A | See Remarks | S - Sale | $6.88 | -504 | 106,391 | 0% | -$3,469 | ||||||
| D | 2021-02-22 | FULC | Fulcrum Therapeutics, Inc. | Thomson Peter G. | VP Finance, Accounting | S - Sale+OE | $14.72 | -5,000 | 15,212 | -25% | -$73,582 | |||||
| D | 2021-02-22 | BPMC | Blueprint Medicines Corp | Dorsch Marion | Chief Scientific Officer | S - Sale+OE | $100.00 | -7,578 | 15,250 | -33% | -$757,800 | |||||
2021-02-22 | ARQT | Arcutis Biotherapeutics, Inc. | Chaudhuri Bhaskar | Dir | S - Sale | $35.52 | -10,000 | 931,372 | -1% | -$355,191 | ||||||
2021-02-15 | QURE | Uniqure N.V. | Kapusta Matthew C | CEO, CFO, MD | S - Sale | $35.38 | -3,800 | 222,938 | -2% | -$134,452 | ||||||
2021-02-23 | MEIP | Mei Pharma, Inc. | Driscoll Frederick W | Dir | S - Sale | $4.03 | -25,000 | 37,500 | -40% | -$100,625 | ||||||
2021-02-23 | SCPS | Scopus Biopharma Inc. | Lamstein Joshua R | COB | P - Purchase | $9.34 | +500 | 117,297 | 0% | +$4,670 | ||||||
2021-02-19 | APLT | Applied Therapeutics Inc. | Kanter Stacy J. | Dir | P - Purchase | $22.86 | +6,500 | 13,000 | +100% | +$148,590 | ||||||
2021-02-23 | SCPS | Scopus Biopharma Inc. | Greenspan IRA Scott | Exec Committee COB | P - Purchase | $9.65 | +1,500 | 87,325 | +2% | +$14,474 | ||||||
| D | 2021-02-22 | ABT | Abbott Laboratories | Moreland Mary K | EVP | S - Sale+OE | $121.83 | -400 | 86,532 | 0% | -$48,734 | |||||
2021-02-19 | ZTS | Zoetis Inc. | Scully Robert W | Dir | P - Purchase | $164.68 | +7,590 | 7,590 | New | +$1,249,931 | ||||||
2021-02-22 | HZNP | Horizon Therapeutics Public Ltd Co | Karnani Vikram | EVP, Pres, International | S - Sale | $87.19 | -8,358 | 104,165 | -7% | -$728,722 | ||||||
2021-02-22 | HZNP | Horizon Therapeutics Public Ltd Co | Konstantinovsky Irina | EVP, Chief HR Off | S - Sale | $87.22 | -5,698 | 81,677 | -7% | -$496,987 | ||||||
| M | 2021-02-19 | PHAT | Phathom Pharmaceuticals, Inc. | Socks David A | Dir | S - Sale | $46.49 | -70,000 | 1,436,048 | -5% | -$3,254,612 | |||||
| D | 2021-02-22 | NRIX | Nurix Therapeutics, Inc. | Van Houte Hans | CFO | S - Sale+OE | $39.93 | -5,330 | 0 | -100% | -$212,839 | |||||
| DM | 2021-02-19 | CNST | Constellation Pharmaceuticals Inc | Reeve Emma | CFO | S - Sale+OE | $37.64 | -10,270 | 0 | -100% | -$386,591 | |||||
| D | 2021-02-19 | STOK | Stoke Therapeutics, Inc. | Tzianabos Arthur | Dir | S - Sale+OE | $60.67 | -10,000 | 0 | -100% | -$606,652 | |||||
2021-02-22 | SDGR | Schrodinger, Inc. | Tran Yvonne | EVP, GC | S - Sale | $113.66 | -10,000 | 17,131 | -37% | -$1,136,586 | ||||||
| DM | 2021-02-19 | OMER | Omeros Corp | Jacobsen Michael A | VP Finance, CAO | S - Sale+OE | $22.93 | -18,100 | 14,000 | -56% | -$414,968 | |||||
| DM | 2021-02-19 | SPPI | Spectrum Pharmaceuticals Inc | Turgeon Joseph W. | CEO, Pres | S - Sale+OE | $3.68 | -14,757 | 634,900 | -2% | -$54,369 | |||||
| D | 2021-02-19 | ZTS | Zoetis Inc. | Alaix Juan Ramon | Dir | S - Sale+OE | $160.55 | -133,070 | 214,307 | -38% | -$21,363,973 | |||||
| DM | 2021-02-19 | KIN | Kindred Biosciences, Inc. | Bevers Denise | Dir | S - Sale+OE | $5.00 | -4,627 | 143,835 | -3% | -$23,135 | |||||
| DM | 2021-02-19 | SPPI | Spectrum Pharmaceuticals Inc | McGahan Keith M | GC | S - Sale+OE | $3.69 | -7,295 | 353,762 | -2% | -$26,904 | |||||
| DM | 2021-02-19 | SPPI | Spectrum Pharmaceuticals Inc | Gustafson Kurt A | EVP, CFO | S - Sale+OE | $3.68 | -8,672 | 448,974 | -2% | -$31,912 | |||||
2021-02-22 | TYME | Tyme Technologies, Inc. | Demurjian Michael | 10% | S - Sale | $2.43 | -20,000 | 24,838,546 | 0% | -$48,614 | ||||||
| DM | 2021-02-19 | SPPI | Spectrum Pharmaceuticals Inc | Riga Thomas J | EVP, COO, CCO | S - Sale+OE | $3.68 | -10,018 | 468,789 | -2% | -$36,900 | |||||
2021-02-19 | SNSE | Sensei Biotherapeutics, Inc. | Peyer James | Dir, 10% | P - Purchase | $19.77 | +11,786 | 4,702,692 | 0% | +$233,009 | ||||||
2021-02-19 | SNSE | Sensei Biotherapeutics, Inc. | Cambrian Biopharma Inc | 10% | P - Purchase | $19.77 | +11,786 | 4,702,692 | 0% | +$233,009 | ||||||
| D | 2021-02-19 | ABEO | Abeona Therapeutics Inc. | Mann Paul Elliot | Dir | S - Sale+OE | $2.38 | -45,566 | 0 | -100% | -$108,502 | |||||
2021-02-19 | ABEO | Abeona Therapeutics Inc. | Wider Todd | Dir | S - Sale | $2.39 | -251,625 | 25,000 | -91% | -$601,057 | ||||||
| A | 2021-02-18 | PRTA | Prothena Corp Public Ltd Co | Ecor1 Capital, LLC | 10% | P - Purchase | $23.65 | +44,100 | 10,104,080 | 0% | +$1,043,075 | |||||
| D | 2021-02-19 | RARE | Ultragenyx Pharmaceutical Inc. | Aliski William | Dir | S - Sale+OE | $149.01 | -7,500 | 145,510 | -5% | -$1,117,575 | |||||
| M | 2021-02-19 | MORF | Morphic Holding, Inc. | Omega Fund V, L.P. | Dir | S - Sale | $35.18 | -10,859 | 2,598,092 | 0% | -$382,044 | |||||
2021-02-22 | SVRA | Savara Inc | Pauls Matthew | CEO | P - Purchase | $1.74 | +28,700 | 256,622 | +13% | +$50,038 | ||||||
2021-02-22 | SCPS | Scopus Biopharma Inc. | Lamstein Joshua R | COB | P - Purchase | $9.99 | +100 | 116,797 | 0% | +$999 | ||||||
2021-02-22 | SCPS | Scopus Biopharma Inc. | Greenspan IRA Scott | Exec Committee COB | P - Purchase | $10.05 | +450 | 5,350 | +9% | +$4,523 | ||||||
2021-02-09 | CBIO | Catalyst Biosciences, Inc. | Usman Nassim | Pres, CEO | P - Purchase | $4.81 | +582 | 21,798 | +3% | +$2,799 | ||||||
2021-02-09 | CBIO | Catalyst Biosciences, Inc. | Levy Howard | Chief Medical Officer | P - Purchase | $4.81 | +1,670 | 23,390 | +8% | +$8,033 | ||||||
| D | 2021-02-19 | BMRN | Biomarin Pharmaceutical Inc | Bienaime Jean Jacques | CEO | S - Sale+OE | $83.58 | -7,000 | 543,085 | -1% | -$585,060 | |||||
| M | 2021-02-18 | PCSA | Processa Pharmaceuticals, Inc. | Besser James E | 10% | S - Sale | $11.49 | -28,929 | 1,501,071 | -2% | -$332,289 | |||||
2021-02-18 | KPTI | Karyopharm Therapeutics Inc. | Shah Jatin | EVP, Chief Medical Officer | S - Sale | $14.83 | -1,186 | 51,791 | -2% | -$17,590 | ||||||
2021-02-18 | KPTI | Karyopharm Therapeutics Inc. | Frenkel Ran | EVP, Chief Dev. Officer | S - Sale | $14.83 | -2,887 | 46,126 | -6% | -$42,818 | ||||||
2021-02-18 | KPTI | Karyopharm Therapeutics Inc. | Shacham Sharon | Pres, CSO | S - Sale | $14.83 | -18,990 | 1,351,578 | -1% | -$281,644 | ||||||
| D | 2021-02-19 | ITCI | Intra-Cellular Therapies, Inc. | Durgam Suresh K. | Chief Medical Officer | S - Sale+OE | $39.25 | -2,734 | 23,104 | -11% | -$107,310 | |||||
2021-02-18 | KPTI | Karyopharm Therapeutics Inc. | Kauffman Michael | CEO | S - Sale | $14.83 | -18,990 | 1,351,578 | -1% | -$281,644 | ||||||
| D | 2021-02-19 | ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | S - Sale+OE | $39.22 | -5,184 | 45,339 | -10% | -$203,308 | |||||
| D | 2021-02-19 | ITCI | Intra-Cellular Therapies, Inc. | Hineline Lawrence J. | SVP of Finance CFO | S - Sale+OE | $39.23 | -10,442 | 0 | -100% | -$409,625 | |||||
| D | 2021-02-19 | ITCI | Intra-Cellular Therapies, Inc. | Halstead Michael | EVP, GC | S - Sale+OE | $39.24 | -11,139 | 0 | -100% | -$437,133 | |||||
| D | 2021-02-19 | ITCI | Intra-Cellular Therapies, Inc. | Mates Sharon | COB, Pres, CEO | S - Sale+OE | $39.23 | -27,847 | 1,133,392 | -2% | -$1,092,436 | |||||
| D | 2021-02-19 | SDGR | Schrodinger, Inc. | D'Cruz Cony | EVP, Chief Business Officer | S - Sale+OE | $102.00 | -4,800 | 153,082 | -3% | -$489,600 | |||||
| D | 2021-02-19 | ZTS | Zoetis Inc. | Lagano Roxanne | EVP | S - Sale+OE | $167.88 | -6,000 | 42,083 | -12% | -$1,007,280 | |||||
| D | 2021-02-18 | ZTS | Zoetis Inc. | Chen Heidi C. | EVP | S - Sale+OE | $170.04 | -600 | 24,645 | -2% | -$102,024 | |||||
2021-02-18 | PRTA | Prothena Corp Public Ltd Co | Ecor1 Capital, LLC | 10% | P - Purchase | $3.68 | +44,100 | 10,104,080 | 0% | +$162,103 | ||||||
| D | 2021-02-18 | NRIX | Nurix Therapeutics, Inc. | Van Houte Hans | CFO | S - Sale+OE | $35.46 | -13,583 | 0 | -100% | -$481,621 | |||||
| D | 2021-02-18 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $35.88 | -2,000 | 0 | -100% | -$71,750 | |||||
| D | 2021-02-18 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $36.27 | -800 | 12,000 | -6% | -$29,018 | |||||
| D | 2021-02-18 | NRIX | Nurix Therapeutics, Inc. | Beaurang Pierre | Chief Business Officer | S - Sale+OE | $35.49 | -15,000 | 0 | -100% | -$532,352 | |||||
| D | 2021-02-19 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $4.77 | +500,000 | 225,067,822 | 0% | +$2,383,455 | |||||
| D | 2021-02-18 | BMRN | Biomarin Pharmaceutical Inc | Bienaime Jean Jacques | CEO | S - Sale+OE | $85.08 | -7,000 | 543,085 | -1% | -$595,560 | |||||
| D | 2021-02-17 | BCEL | Atreca, Inc. | Greenberg Norman Michael | Chief Scientific Officer | S - Sale+OE | $18.95 | -5,000 | 0 | -100% | -$94,752 | |||||
| M | 2021-02-17 | SDGR | Schrodinger, Inc. | Shaw David E | 10% | S - Sale | $102.64 | -342,759 | 9,319,847 | -4% | -$35,179,809 | |||||
| D | 2021-02-17 | BTAI | Bioxcel Therapeutics, Inc. | O'Neill Vincent | Chief Medical Officer | S - Sale+OE | $55.58 | -25,000 | 0 | -100% | -$1,389,459 | |||||
| D | 2021-02-17 | FGEN | Fibrogen Inc | Kurkijarvi Kalevi | Dir | S - Sale+OE | $52.40 | -6,000 | 33,100 | -15% | -$314,383 | |||||
| D | 2021-02-17 | DBTX | Decibel Therapeutics, Inc. | Orbimed Advisors LLC | Dir, 10% | P - Purchase | $18.00 | +1,666,666 | 883,418 | -213% | +$29,999,988 | |||||
| D | 2021-02-17 | DBTX | Decibel Therapeutics, Inc. | Foy Matthew | Dir, 10% | P - Purchase | $18.00 | +150,000 | 1,183,663 | +15% | +$2,700,000 | |||||
| D | 2021-02-17 | DBTX | Decibel Therapeutics, Inc. | Casdin Partners Master Fund, L.P. | 10% | P - Purchase | $18.00 | +575,000 | 1,121,421 | +105% | +$10,350,000 | |||||
| D | 2021-02-17 | DBTX | Decibel Therapeutics, Inc. | Thompson Peter A. | Dir, 10% | P - Purchase | $18.00 | +1,666,666 | 883,418 | -213% | +$29,999,988 | |||||
| D | 2021-02-18 | PRTA | Prothena Corp Public Ltd Co | Zago Wagner M. | Chief Scientific Officer | S - Sale+OE | $25.50 | -7,540 | 0 | -100% | -$192,270 | |||||
2021-02-17 | VRPX | Virpax Pharmaceuticals, Inc. | Jacob Gary S | Dir | P - Purchase | $6.79 | +3,500 | 3,500 | New | +$23,762 | ||||||
| M | 2021-02-17 | HGEN | Humanigen, Inc | Nomis Bay Ltd. | 10% | S - Sale | $22.25 | -89,408 | 5,765,762 | -2% | -$1,989,619 | |||||
2021-02-17 | CNST | Constellation Pharmaceuticals Inc | Column Group L P | 10% | S - Sale | $36.95 | -10,000 | 6,230,638 | 0% | -$369,503 | ||||||
2021-02-17 | CNST | Constellation Pharmaceuticals Inc | Column Group L P | 10% | S - Sale | $36.95 | -10,000 | 6,230,638 | 0% | -$369,503 | ||||||
2021-02-18 | MTEM | Molecular Templates, Inc. | Biotech Target N V | 10% | P - Purchase | $12.65 | +1,185,770 | 7,726,101 | +18% | +$14,999,991 | ||||||
2021-02-18 | GRTX | Galera Therapeutics, Inc. | Novo Holdings A/s | 10% | S - Sale | $10.58 | -500,000 | 2,459,021 | -17% | -$5,290,000 | ||||||
2021-02-17 | CRVS | Corvus Pharmaceuticals, Inc. | Orbimed Advisors LLC | Dir, 10% | P - Purchase | $3.50 | +1,285,714 | 8,053,298 | +19% | +$4,499,999 | ||||||
| D | 2021-02-17 | DBTX | Decibel Therapeutics, Inc. | Glaxosmithkline Plc | Dir | P - Purchase | $18.00 | +150,000 | 1,183,663 | +15% | +$2,700,000 | |||||
2021-02-17 | CRVS | Corvus Pharmaceuticals, Inc. | Thompson Peter A. | Dir, 10% | P - Purchase | $3.50 | +1,285,714 | 8,053,298 | +19% | +$4,499,999 | ||||||
| D | 2021-02-17 | NEXI | Neximmune, Inc. | Jones Kristi | COO | P - Purchase | $17.00 | +911 | 63,078 | +1% | +$15,487 | |||||
2021-02-17 | NEXI | Neximmune, Inc. | Zeldis Jerome B | EVP of Research, Dev | P - Purchase | $17.00 | +5,882 | 5,882 | New | +$99,994 | ||||||
| D | 2021-02-17 | NEXI | Neximmune, Inc. | Verstandig Grant | Dir | P - Purchase | $17.00 | +175,000 | 714,895 | +32% | +$2,975,000 | |||||
2021-02-18 | VRTX | Vertex Pharmaceuticals Inc / Ma | Silva Paul M | SVP, Chief Accounting Officer | S - Sale | $211.83 | -4,295 | 16,997 | -20% | -$909,828 | ||||||
| D | 2021-02-17 | NEXI | Neximmune, Inc. | Barer Sol J | Dir | P - Purchase | $17.00 | +60,000 | 3,252,404 | +2% | +$1,020,000 | |||||
2021-02-18 | VRTX | Vertex Pharmaceuticals Inc / Ma | Sachdev Amit | EVP, Chief Patient Officer | S - Sale | $211.83 | -9,264 | 54,915 | -14% | -$1,962,366 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |